Yokouchi Hiroshi, Chamoto Kenji, Wakita Daiko, Noguchi Daisuke, Yamazaki Koichi, Dosaka-Akita Hirotoshi, Nishimura Masaharu, Ikeda Hiroaki, Nishimura Takashi
Division of Immunoregulation, Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, Kita-ku, Sapporo 060-8638, Japan.
Cancer Sci. 2006 Feb;97(2):148-54. doi: 10.1111/j.1349-7006.2006.00149.x.
Peptide-MHC tetramers have been engineered to allow accurate detection of antigen-specific cytotoxic C lymphocytes (CTL) by flow cytometry. Here, we propose a novel use for peptide-MHC tetramers in the specific and sensitive analysis of the cytotoxic function of antigen-specific CTL by blocking MHC-restricted antigen-specific cytotoxicity. We found that pretreatment of ovalbumin (OVA)-specific CD8(+) CTL (OT-1 CTL), derived from OT-1 T-cell receptor (TCR)-transgenic mice, with OVA(257-264) peptide-H-2K(b) tetramer caused a marked inhibition of the cytotoxicity against OVA-expressing EG-7 tumor cells. OVA(257-264) peptide-H-2K(b) tetramer did not block the cytotoxicity mediated by 2C mouse (H-2(b))-derived CD8(+) CTL, which recognize allo (H-2L(d)) antigens. Moreover, OT-I CTL activity was not inhibited by an irrelevant HBV(208-216) peptide-H-2K(b) tetramer. These results indicate that the blocking of CTL activity with peptide-MHC tetramer was caused by interference with the interaction between the TCR and H-2K(b)-OVA(257-264) peptide complex, but not with the CD8-MHC class I interaction. The blocking activity of OVA(257-264) peptide-H-2K(b) tetramer was reversible because OT-I CTL pretreated with the tetramer recovered their cytotoxicity after culturing with interleukin-2 for 24 h. The same results were also demonstrated in freshly isolated, in vivo-primed OT-1 CTL sorted by the tetramer. These results demonstrate that peptide-MHC tetramer is a useful tool for defining MHC-restricted antigen-specific CTL function. Moreover, our finding implies that the measurement of CTL activity immediately after tetramer-guided sorting is not a suitable method for evaluating the function of in vivo-induced tetramer-positive CTL. We believe that the tetramer-blocking assay presented here will be useful for functionally monitor the induction of MHC-restricted antigen-specific CTL during vaccination therapy against tumor and infectious diseases.
肽 - 主要组织相容性复合体(MHC)四聚体已被设计用于通过流式细胞术准确检测抗原特异性细胞毒性T淋巴细胞(CTL)。在此,我们提出肽 - MHC四聚体在通过阻断MHC限制的抗原特异性细胞毒性来特异性和灵敏地分析抗原特异性CTL的细胞毒性功能方面的一种新用途。我们发现,用卵清蛋白(OVA)(257 - 264)肽 - H - 2K(b)四聚体预处理源自OT - 1 T细胞受体(TCR)转基因小鼠的OVA特异性CD8(+) CTL(OT - 1 CTL),会显著抑制对表达OVA的EG - 7肿瘤细胞的细胞毒性。OVA(257 - 264)肽 - H - 2K(b)四聚体不会阻断由识别同种异体(H - 2L(d))抗原的2C小鼠(H - 2(b))来源的CD8(+) CTL介导的细胞毒性。此外,OT - I CTL活性不会被不相关的乙肝病毒(HBV)(208 - 216)肽 - H - 2K(b)四聚体抑制。这些结果表明,肽 - MHC四聚体对CTL活性的阻断是由于干扰了TCR与H - 2K(b) - OVA(257 - 264)肽复合物之间的相互作用,而不是与CD8 - I类MHC的相互作用。OVA(257 - 264)肽 - H - 2K(b)四聚体的阻断活性是可逆的,因为用四聚体预处理的OT - I CTL在与白细胞介素 - 2培养24小时后恢复了它们的细胞毒性。在通过四聚体分选的新鲜分离的、体内致敏的OT - 1 CTL中也证明了相同的结果。这些结果表明,肽 - MHC四聚体是定义MHC限制的抗原特异性CTL功能的有用工具。此外,我们的发现意味着在四聚体引导分选后立即测量CTL活性不是评估体内诱导的四聚体阳性CTL功能的合适方法。我们相信这里介绍的四聚体阻断测定法将有助于在针对肿瘤和传染病的疫苗治疗期间从功能上监测MHC限制的抗原特异性CTL的诱导情况。